MedPath

Safety and Efficacy of Vilazodone in Adolescent Patients With Major Depressive Disorder

Phase 3
Completed
Conditions
Major Depressive Disorder
Interventions
Drug: Placebo
Registration Number
NCT01878292
Lead Sponsor
Forest Laboratories
Brief Summary

The purpose of this study is to evaluate the efficacy, safety, and tolerability of vilazodone relative to placebo in adolescent outpatients (12-17) with major depressive disorder.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
529
Inclusion Criteria
  • Male or Female outpatients between 12-17 years of age
  • Primary diagnosis of major depressive disorder (MDD)
  • Children's Depression Rating Scale-Revised (CDRS-R) score of 40 or greater
  • Clinical Global Impressions-Severity (CGI-S) score of 4 or greater
Exclusion Criteria
  • Current (past 3 months) principal Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision (DSM-IV-TR) based diagnosis of an axis disorder other than major depressive disorder (MDD) that is the primary focus of treatment.
  • History of suicidal behavior, or requires precaution against suicide
  • Not generally healthy medical condition
  • Seizure disorder

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PlaceboPlaceboDose-matched placebo tablets, once per day, oral administration
vilazodone 30 mgVilazodone30 mg vilazodone tablets, once per day, oral administration
Vilazodone 15 mgVilazodone15 mg vilazodone tablets, once per day, oral administration
Primary Outcome Measures
NameTimeMethod
Change in Children's Depression Rating Scale - Revised (CDRS-R) Total ScoreFrom Baseline to week 8

The Children's Depression Rating Scale-Revised (CDRS-R) total score ranges from 17 (minimal or no symptoms of depression) to 133 (indicative of depression) is a semi-structured, clinician-rated instrument designed for use with children and adolescents between the ages of 6 to 17 years of age and their caregivers. The CDRS-R evaluates the presence and severity of symptoms commonly associated with depression in childhood.

Secondary Outcome Measures
NameTimeMethod
Change in Clinical Global Impressions-Severity (CGI-S) ScoreFrom Baseline to Week 8

The Clinical Global Impressions-Severity (CGI-S) is a clinician-rated instrument used to rate the severity of the patient's current state of mental illness compared with the clinician's total experience with patients with major depressive disorder (MDD). The severity of the patient's MDD was rated on a scale from 1 to 7, with 1 indicating a normal state and 7 indicating a patient who is among the most extremely ill patients.

Trial Locations

Locations (52)

Forest Investigative Site 054

🇺🇸

Baltimore, Maryland, United States

Forest Investigative Site 034

🇺🇸

Oakland Park, Florida, United States

Forest Investigative Site 030

🇺🇸

Roswell, Georgia, United States

Forest Investigative Site 032

🇺🇸

Libertyville, Illinois, United States

Forest Investigative Site 048

🇺🇸

Naperville, Illinois, United States

Forest Investigative Site 051

🇺🇸

Terre Haute, Indiana, United States

Forest Investigative Site 070

🇺🇸

Lake Charles, Louisiana, United States

Forest Investigative Site 050

🇺🇸

Baltimore, Maryland, United States

Forest Investigative Site 026

🇺🇸

Watertown, Massachusetts, United States

Forest Investigative Site 049

🇺🇸

Rockville, Maryland, United States

Forest Investigative Site 024

🇺🇸

Rochester Hills, Michigan, United States

Forest Investigative Site 015

🇺🇸

Creve Coeur, Missouri, United States

Forest Investigative Site 055

🇺🇸

Saint Charles, Missouri, United States

Forest Investigative Site 072

🇺🇸

Saint Louis, Missouri, United States

Forest Investigative Site 007

🇺🇸

Cherry Hill, New Jersey, United States

Forest Investigative Site 071

🇺🇸

Neptune, New Jersey, United States

Forest Investigative Site 008

🇺🇸

Albuquerque, New Mexico, United States

Forest Investigative Site 057

🇺🇸

Rochester, New York, United States

Forest Investigative Site 021

🇺🇸

Canton, Ohio, United States

Forest Investigative Site 029

🇺🇸

Columbus, Ohio, United States

Forest Investigative Site 053

🇺🇸

Avon Lake, Ohio, United States

Forest Investigative Site 040

🇺🇸

Philadelphia, Pennsylvania, United States

Forest Investigative Site 065

🇺🇸

Tulsa, Oklahoma, United States

Forest Investigative Site 074

🇺🇸

Charleston, South Carolina, United States

Forest Investigative Site 062

🇺🇸

Memphis, Tennessee, United States

Forest Investigative Site 001

🇺🇸

Dallas, Texas, United States

Forest Investigative Site 045

🇺🇸

The Woodlands, Texas, United States

Forest Investigative Site 041

🇺🇸

Plano, Texas, United States

Forest Investigative Site 019

🇺🇸

Clinton, Utah, United States

Forest Investigative Site 035

🇺🇸

Bellevue, Washington, United States

Forest Investigative Site 060

🇺🇸

Richmond, Virginia, United States

Forest Investigative Site 068

🇺🇸

Bothell, Washington, United States

Forest Investigative Site 022

🇺🇸

Kirkland, Washington, United States

Forest Investigative Site 052

🇺🇸

Los Angeles, California, United States

Forest Investigative Site 073

🇺🇸

Imperial, California, United States

Forest Investigative Site 023

🇺🇸

Murrieta, California, United States

Forest Investigative Site 014

🇺🇸

Atlanta, Georgia, United States

Forest Investigative Site 004

🇺🇸

Orange, California, United States

Forest Investigative Site 006

🇺🇸

Washington, District of Columbia, United States

Forest Investigative Site 039

🇺🇸

Gainesville, Florida, United States

Forest Investigative Site 009

🇺🇸

Jacksonville Beach, Florida, United States

Forest Investigative Site 013

🇺🇸

Overland Park, Kansas, United States

Forest Investigative Site 037

🇺🇸

San Diego, California, United States

Forest Investigative Site 016

🇺🇸

Orlando, Florida, United States

Forest Investigative Site 063

🇺🇸

Miami, Florida, United States

Forest Investigative Site 064

🇺🇸

Orlando, Florida, United States

Forest Investigative Site 066

🇺🇸

Las Vegas, Nevada, United States

Forest Investigative Site 059

🇺🇸

Durham, North Carolina, United States

Forest Investigative Site 012

🇺🇸

Cincinnati, Ohio, United States

Forest Investigative Site 018

🇺🇸

Oklahoma City, Oklahoma, United States

Forest Investigative Site 011

🇺🇸

Oklahoma City, Oklahoma, United States

Forest Investigative Site 027

🇺🇸

Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath